Five-Year Risk of Repeat SUI, POP Surgery Less Than 10 Percent

Share this content:
Five-Year Risk of Repeat SUI, POP Surgery Less Than 10 Percent
Five-Year Risk of Repeat SUI, POP Surgery Less Than 10 Percent

TUESDAY, May 23, 2017 (HealthDay News) -- For women undergoing surgery for stress urinary incontinence (SUI) and pelvic organ prolapse (POP), the risk of repeat procedures is less than 10 percent, with increased risks for older women and initial POP surgery, according to a study published in the June issue of Obstetrics & Gynecology.

Jennifer M. Wu, M.D., M.P.H., from the University of North Carolina in Chapel Hill, and colleagues conducted a retrospective cohort study using a nationwide database to examine the five-year risk and timing of repeat SUI and POP procedures among women aged 18 to 84 years. The index procedures were identified for SUI or POP after at least three years of continuous enrollment without a prior procedure. Based on the index procedure, women were defined as: SUI surgery only (48,196 women), POP surgery only (49,120 women), and both SUI and POP surgery (40,687 women).

The researchers found that after any index procedure, the overall cumulative incidence of a subsequent SUI or POP surgery within five years was 7.8 and 9.9 percent for women younger than 65 years and age 65 years or older, respectively. Lower cumulative incidence was seen if the initial surgery was SUI only, while cumulative incidence was higher if an initial POP procedure was performed (POP only or SUI and POP).

"The five-year risk of undergoing a repeat SUI or POP surgery was less than 10 percent with higher risks for women 65 years or older and for those who underwent an initial POP surgery," the authors write.

One author disclosed financial ties to Pelvalon and Boston Scientific.

Abstract/ Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Osimertinib Tops Standard EGFR-TKI for EGFR NSCLC

Osimertinib Tops Standard EGFR-TKI for <i>EGFR</i>&#43; NSCLC

Significantly longer median progression-free survival for osimertinib in previously untreated NSCLC

Distinct Features for Drug Use-Related Endophthalmitis

Distinct Features for Drug Use-Related Endophthalmitis

Injection drug users have fewer comorbidities and more improvement in visual acuity after intervention

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Nonmedical use of prescription drugs linked to dating violence for male, female high school students

is free, fast, and customized just for you!

Already a member?

Sign In Now »